摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-氨基-1H-吲唑-1-羧酸叔丁酯 | 801315-74-2

中文名称
4-氨基-1H-吲唑-1-羧酸叔丁酯
中文别名
1-Boc-4-氨基引唑;1-BOC-4-氨基引唑
英文名称
tert-butyl 4-amino-1H-indazole-1-carboxylate
英文别名
tert-butyl 4-aminoindazole-1-carboxylate
4-氨基-1H-吲唑-1-羧酸叔丁酯化学式
CAS
801315-74-2
化学式
C12H15N3O2
mdl
MFCD11052618
分子量
233.27
InChiKey
LBOHJOLQKZNKFB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    395.3±34.0 °C(Predicted)
  • 密度:
    1.24±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    17
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.333
  • 拓扑面积:
    70.1
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2933990090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    应存于阴凉避光处,并置于惰性气体中保存。

SDS

SDS:4da327afa3c5dd530b7197c3156360e1
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: tert-Butyl 4-amino-1h-indazole-1-carboxylate
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: tert-Butyl 4-amino-1h-indazole-1-carboxylate
CAS number: 801315-74-2

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H15N3O2
Molecular weight: 233.3

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-氨基-1H-吲唑-1-羧酸叔丁酯N-氯代丁二酰亚胺 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 16.0h, 以14 g的产率得到tert-butyl 4-amino-7-chloro-1H-indazole-1-carboxylate
    参考文献:
    名称:
    [EN] BENZOTHIADIAZINE COMPOUNDS
    [FR] COMPOSÉS BENZOTHIADIAZINE
    摘要:
    本发明涉及取代苯并噻二嗪衍生物。具体而言,本发明涉及式(I)化合物:其中R、R1、R2、R3、R4和R5定义如下。本发明的化合物是CD73的抑制剂,可用于治疗癌症、前癌综合症和与CD73抑制相关的疾病,如艾滋病、自身免疫病、感染、动脉粥样硬化和缺血-再灌注损伤。因此,本发明进一步涉及包含本发明化合物的药物组合物。本发明更进一步的涉及使用本发明化合物或包含本发明化合物的药物组合物抑制CD73活性和治疗相关疾病的方法。
    公开号:
    WO2017098421A1
  • 作为产物:
    描述:
    4-硝基吲唑三乙胺 作用下, 以 甲醇 为溶剂, 反应 11.67h, 生成 4-氨基-1H-吲唑-1-羧酸叔丁酯
    参考文献:
    名称:
    通过 1,4-oxazep​​ane 环的支架跳跃发现 EP300/CBP 组蛋白乙酰转移酶抑制剂
    摘要:
    EP300 及其旁系同源 CBP 作为组蛋白乙酰转移酶 (HAT) 在翻译后修饰中发挥重要作用。近年来,EP300/CBP抑制作为抗癌治疗靶点受到关注。在这里,我们描述了一种新型的、高选择性的 EP300/CBP 抑制剂化合物11 ( DS17701585 ),通过支架跳跃和基于结构的优化高通量筛选命中1。化合物11 ( DS17701585 ) 在人肺鳞状细胞癌细胞系 LK2 异种移植小鼠模型中显示出 SRY-box 转录因子 2 (SOX2) mRNA 表达的剂量依赖性抑制作用。
    DOI:
    10.1016/j.bmcl.2022.128726
点击查看最新优质反应信息

文献信息

  • [EN] THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE<br/>[FR] DÉRIVÉS DE THIOPHÈNE POUR LE TRAITEMENT DE TROUBLES PROVOQUÉS PAR IGE
    申请人:UCB BIOPHARMA SRL
    公开号:WO2019243550A1
    公开(公告)日:2019-12-26
    Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.
    提供了公式(I)的噻吩生物及其药用可接受的盐。这些化合物对于治疗或预防由IgE引起的疾病具有用途,如过敏、1型超敏反应或家族性鼻窦炎。
  • ヘテロシクロアルキル環を含むアミド誘導体
    申请人:第一三共株式会社
    公开号:JP2020045306A
    公开(公告)日:2020-03-26
    【課題】本発明は、優れたEP300および/またはCREBBPのヒストンアセチルトランスフェラーゼ阻害活性を有する化合物またはその薬理上許容される塩を提供するものである。【解決手段】式(1)で表される化合物またはその薬理上許容される塩。【化1】(ここで、式(1)中の環Q1、環Q2、環Q3、X、およびLは、それぞれ明細書中の定義と同義である。)【選択図】なし
    本发明提供具有优良的EP300和/或CREBBP的组蛋白乙酰转移酶抑制活性的化合物或其药理上可接受的盐。该化合物或其药理上可接受的盐由式(1)表示。在此,环Q1、环Q2、环Q3、X和L在式(1)中分别与说明书中的定义同义。【选择图】无
  • 一类具有TDO、IDO1双重抑制活性的化合物及制备治疗神经退行性疾病药物的用途
    申请人:西华大学
    公开号:CN111689901A
    公开(公告)日:2020-09-22
    本发明提供了式I所示的化合物、或其药学上可接受的盐、或其溶剂合物,其可以选择性地抑制TDO、IDO1,其对TDO和/或IDO1具有明显的抑制效果。此外,本发明制备的化合物具有明显的抗肿瘤效果,对帕森病、阿尔茨海默症也有一定治疗作用,其在药物制备领域具有很好的应用前景。
  • [EN] QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS<br/>[FR] DERIVES DE QUINOLEINE UTILISES EN TANT QU'INHIBITEURS DE LA PHOSPHODIESTERASE
    申请人:GLAXO GROUP LTD
    公开号:WO2004103998A1
    公开(公告)日:2004-12-02
    There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20 and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
    根据本发明提供了化合物的新结构,其化学式为(I)或其药用盐,其中R1、R2、R19、R20和R34如规范中所述,以及制备这些化合物的方法、含有它们的配方和它们在治疗炎症性疾病中的用途。
  • RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF
    申请人:Buckmelter Alexandre J.
    公开号:US20100063066A1
    公开(公告)日:2010-03-11
    Compounds of Formulas (I), (IIA) and (IIIA) are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formulas (I), (IIA) and (IIIA) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    化合物(I)、(IIA)和(IIIA)的配方对抑制Raf激酶和治疗由此介导的疾病很有用。公开了使用化合物(I)、(IIA)和(IIIA)及其立体异构体和药用盐,在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗这些疾病或相关病理状况的方法。
查看更多